Montag & Associates’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.2M | Buy |
7,861
+215
| +3% | +$33K | 0.06% | 224 |
|
|
2025
Q4 | $1.05M | Sell |
7,646
-4
| -0.1% | -$524 | 0.05% | 233 |
|
|
2025
Q3 | $981K | Buy |
7,650
+75
| +1% | +$9.15K | 0.05% | 246 |
|
|
2025
Q2 | $917K | Hold |
7,575
| – | – | 0.04% | 249 |
|
|
2025
Q1 | $874K | Hold |
7,575
| – | – | 0.04% | 252 |
|
|
2024
Q4 | $737K | Hold |
7,575
| – | – | 0.04% | 278 |
|
|
2024
Q3 | $871K | Hold |
7,575
| – | – | 0.04% | 259 |
|
|
2024
Q2 | $806K | Hold |
7,575
| – | – | 0.04% | 255 |
|
|
2024
Q1 | $733K | Sell |
7,575
-398
| -5% | -$40.8K | 0.04% | 283 |
|
|
2023
Q4 | $805K | Sell |
7,973
-103
| -1% | -$9.94K | 0.04% | 255 |
|
|
2023
Q3 | $823K | Sell |
8,076
-191
| -2% | -$19.4K | 0.05% | 241 |
|
|
2023
Q2 | $834K | Buy |
8,267
+99
| +1% | +$9.9K | 0.05% | 232 |
|
|
2023
Q1 | $751K | Sell |
8,168
-9
| -0.1% | -$786 | 0.05% | 244 |
|
|
2022
Q4 | $742K | Sell |
8,177
-384
| -4% | -$32.3K | 0.05% | 231 |
|
|
2022
Q3 | $651K | Buy |
8,561
+2,077
| +32% | +$172K | 0.05% | 239 |
|
|
2022
Q2 | $548K | Hold |
6,484
| – | – | 0.04% | 252 |
|
|
2022
Q1 | $569K | Sell |
6,484
-23
| -0.4% | -$1.99K | 0.03% | 278 |
|
|
2021
Q4 | $569K | Buy |
6,507
+143
| +2% | +$11.9K | 0.03% | 283 |
|
|
2021
Q3 | $520K | Hold |
6,364
| – | – | 0.03% | 289 |
|
|
2021
Q2 | $581K | Hold |
6,364
| – | – | 0.03% | 280 |
|
|
2021
Q1 | $544K | Sell |
6,364
-200
| -3% | -$17.9K | 0.03% | 284 |
|
|
2020
Q4 | $620K | Sell |
6,564
-1,250
| -16% | -$109K | 0.04% | 252 |
|
|
2020
Q3 | $680K | Buy |
7,814
+385
| +5% | +$33.4K | 0.05% | 207 |
|
|
2020
Q2 | $649K | Sell |
7,429
-34
| -0.5% | -$2.94K | 0.06% | 209 |
|
|
2020
Q1 | $615K | Hold |
7,463
| – | – | 0.06% | 202 |
|
|
2019
Q4 | $707K | Sell |
7,463
-27
| -0.4% | -$2.42K | 0.06% | 210 |
|
|
2019
Q3 | $651K | Sell |
7,490
-28
| -0.4% | -$2.51K | 0.06% | 207 |
|
|
2019
Q2 | $686K | Sell |
7,518
-1,053
| -12% | -$89.1K | 0.06% | 200 |
|
|
2019
Q1 | $738K | Sell |
8,571
-254
| -3% | -$20.4K | 0.07% | 197 |
|
|
2018
Q4 | $679K | Buy |
8,825
+1,241
| +16% | +$96.6K | 0.07% | 177 |
|
|
2018
Q3 | $586K | Sell |
7,584
-681
| -8% | -$50.3K | 0.05% | 228 |
|
|
2018
Q2 | $559K | Sell |
8,265
-39,030
| -83% | -$2.69M | 0.06% | 210 |
|
|
2018
Q1 | $3.43M | Buy |
47,295
+31,538
| +200% | +$2.4M | 0.35% | 80 |
|
|
2017
Q4 | $1.19M | Buy |
15,757
+7,673
| +95% | +$579K | 0.11% | 166 |
|
|
2017
Q3 | $622K | Buy |
8,084
+44
| +0.5% | +$3.32K | 0.07% | 182 |
|
|
2017
Q2 | $601K | Hold |
8,040
| – | – | 0.07% | 173 |
|
|
2017
Q1 | $535K | Hold |
8,040
| – | – | 0.06% | 180 |
|
|
2016
Q4 | $525K | Sell |
8,040
-167
| -2% | -$10.8K | 0.06% | 178 |
|
|
2016
Q3 | $581K | Sell |
8,207
-190
| -2% | -$13.8K | 0.07% | 171 |
|
|
2016
Q2 | $621K | Sell |
8,397
-558
| -6% | -$38.5K | 0.08% | 165 |
|
|
2016
Q1 | $581K | Sell |
8,955
-35,857
| -80% | -$2.44M | 0.08% | 162 |
|
|
2015
Q4 | $3.46M | Sell |
44,812
-926
| -2% | -$73.6K | 0.51% | 63 |
|
|
2015
Q3 | $3.77M | Buy |
45,738
+441
| +1% | +$39.2K | 0.59% | 58 |
|
|
2015
Q2 | $3.99M | Sell |
45,297
-3,867
| -8% | -$355K | 0.58% | 57 |
|
|
2015
Q1 | $4.34M | Buy |
49,164
+2,661
| +6% | +$236K | 0.63% | 52 |
|
|
2014
Q4 | $3.86M | Buy |
46,503
+3,404
| +8% | +$282K | 0.58% | 62 |
|
|
2014
Q3 | $3.63M | Sell |
43,099
-3,365
| -7% | -$272K | 0.6% | 58 |
|
|
2014
Q2 | $3.77M | Sell |
46,464
-2,153
| -4% | -$169K | 0.61% | 52 |
|
|
2014
Q1 | $3.7M | Buy |
48,617
+3,582
| +8% | +$261K | 0.63% | 55 |
|
|
2013
Q4 | $3.24M | Buy |
45,035
+25,551
| +131% | +$1.78M | 0.56% | 60 |
|
|
2013
Q3 | $1.34M | Buy |
19,484
+44
| +0.2% | +$2.91K | 0.25% | 111 |
|
|
2013
Q2 | $1.23M | Buy |
+19,440
| New | +$1.26M | 0.25% | 108 |
|
Other funds holding NVS
Montag & Associates's NVS Position: Q1 2026 in Review
Montag & Associates increased its Novartis (NVS) stake by 2.8% in Q1 2026, buying an estimated $33K and bringing the position to 7,861 shares worth $1.2M. The position accounts for 0.06% of the portfolio, ranked #224.
Montag & Associates first reported a position in NVS in Q2 2013 and has held it in 52 quarters since. The position peaked at $4.34M in Q1 2015. 1,591 funds tracked by Wall St. Rank hold NVS as of Q1 2026.
- Montag & Associates held 7,861 shares of Novartis worth $1.2M as of Q1 2026.
- Montag & Associates bought 215 Novartis shares in Q1 2026, an estimated $33K.
- Novartis made up 0.06% of Montag & Associates's portfolio in Q1 2026, its #224 holding.
- Montag & Associates first reported a position in Novartis in Q2 2013 and has held it in 52 quarters since.
- Montag & Associates's Novartis position peaked at $4.34M in Q1 2015.
- 1,591 funds tracked by Wall St. Rank held Novartis as of Q1 2026.
Based on Montag & Associates's 13F filing for Q1 2026, filed 29 Apr 2026.